1767 Article Views
Publication Date: 28 Apr 2008
Journal: Clinical Medicine Insights: Oncology Clinical Medicine: Oncology 2008:2 357-362
Abstract Antonio Salas1,2, Ana Vega2,3, Roger L. Milne5, Manuel García-Magariños2, Álvaro Ruibal4, Javier Benítez5,6 and Ángel Carracedo1,2,3
1Unidade de Xenética, Instituto de Medicina Legal, Facultad de Medicina, Universidad de Santiago de Compostela, 15782, Galicia, Spain. 2Grupo de Medicina Xenómica, CIBERER, Universidad de Santiago de Compostela, Galicia, Spain. 3Fundación Pública Galega de Medicina Xenómica (FPGMX)-Consellería de Sanidad Santiago de Compostela, 15706, Galicia, Spain. 4Servicio de Medicina Nuclear, Hospital Clínico Universitario, Santiago. 5Centro Nacional de Genotipado (CeGen), Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain. 6Programa de Genética del Cáncer Humano, CIBERER, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
Abstract
It has been proposed that the excess of familiar risk associated with breast cancer could be explained by the cumulative effect of multiple weakly predisposing alleles. The transcriptional repressor FBI1, also known as Pokemon, has recently been identified as a critical factor in oncogenesis. This protein is encoded by the ZBTB7 gene. Here we aimed to determine whether polymorphisms in ZBTB7 are associated with breast cancer risk in a sample of cases and controls collected in hospitals from North and Central Spanish patients. We genotyped 15 SNPs in ZBTB7, including the flanking regions, with an average coverage of 1 SNP/2.4 Kb, in 360 sporadic breast cancer cases and 402 controls. Comparison of allele, genotype and haplotype frequencies between cases and controls did not reveal associations using Pearson’s chi-square test and a permutation procedure to correct for multiple test. In this, the first study of the ZBTB7 gene in relation to, sporadic breast cancer, we found no evidence of an association.
Discussion
No comments yet...Be the first to comment.
It is an absolute pleasure serving as a peer reviewer for Libertas Academia. The review process was efficient and easy to navigate. I am looking forward to peer review additional articles in the future.Dr Samuel S. Grossman PharmD, CDE (New York Harbor Health Care System, New York, NY, USA) What our authors say
Copyright © 2010 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)